{"id":4900,"date":"2022-02-23T08:49:26","date_gmt":"2022-02-23T13:49:26","guid":{"rendered":"https:\/\/www.wmfc.ca\/?p=4900"},"modified":"2022-05-26T17:45:39","modified_gmt":"2022-05-26T21:45:39","slug":"un-autre-essai-clinique-disponible-au-canada-le-nemtabrutinib","status":"publish","type":"post","link":"https:\/\/www.wmfc.ca\/fr\/2022\/02\/23\/another-clinical-trial-available-in-canada-nemtabrutinib\/","title":{"rendered":"Nemtabrutinib: Un autre essai clinique disponible au Canada"},"content":{"rendered":"<p>Le nemtabrutinib (alias MK-1026 et ARQ 531) est un inhibiteur de BTK, mais dans le cas du  Pirtobrutinib (LOXO-305), il a un comportement de liaison r\u00e9versible (\"non covalent\") au site BTK.  (Pour plus d'informations sur sa chimie, <a href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/arq-531\" target=\"_blank\" rel=\"noopener\">consulter ce site<\/a>.)<\/p>\n<p>Un essai ouvert de phase 2 du Nemtabrutinib recrute actuellement dans le monde entier, <span style=\"text-decoration: underline;\"><strong>incluant des patients atteints de la MW<\/strong><\/span>. En particulier, en date du  24 mai 2022, trois emplacements canadiens sont inclus :<\/p>\n<ul>\n<li>The Tom Baker Cancer Centre, Calgary, AB ; le coordinateur de l'\u00e9tude peut \u00eatre  rejoint au (403) 521-3723.<\/li>\n<li>L'H\u00f4pital g\u00e9n\u00e9ral juif, Montr\u00e9al, QC ; le coordinateur de l'\u00e9tude peut \u00eatre rejoint au  (514) 340-8222, x24572.<\/li>\n<li>L'H\u00f4pital d'Ottawa, Ottawa, Ontario ; on peut rejoindre  le coordonnateur de l'\u00e9tude au num\u00e9ro suivant:  (613) 737-7700 ; <em>Nota bene: ceci est  le num\u00e9ro g\u00e9n\u00e9rique de l'h\u00f4pital, SVP demander ensuite  le d\u00e9partement d'h\u00e9matologie.<\/em>)<\/li>\n<\/ul>\n<p>Cette \u00e9tude est <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04728893\" target=\"_blank\" rel=\"noopener\">list\u00e9s ici sur le site web de ClinicalTrials<\/a>.<\/p>\n<p>Il s'agit d'une \u00e9tude importante pour les personnes atteintes de la MW au Canada, car les crit\u00e8res d'\u00e9ligibilit\u00e9 demandent sp\u00e9cifiquement aux patients atteints de la MW \"qui sont en rechute ou r\u00e9fractaires aux th\u00e9rapies standard pour la MW, y compris la chimio-immunoth\u00e9rapie et un BTKi covalent irr\u00e9versible\".<\/p>","protected":false},"excerpt":{"rendered":"<p>Nemtabrutinib (a.k.a. MK-1026 and ARQ 531) is a BTK inhibitor, but, similar to Pirtobrutinib (LOXO-305), has a reversible (&#8220;non-covalent&#8221;) binding behaviour to the BTK site.\u00a0 (For more information on its chemistry, see this site.) An open-label phase 2 trial of Nemtabrutinib, including WM patients, is now recruiting at locations around the world.\u00a0 In particular, three (as of May 24\/2022) Canadian locations are included: The Tom Baker Cancer Centre, Calgary, AB; Study co-ordinator is at (403) 521-3723 The Jewish General Hospital, Montreal, QC; Study co-ordinator is at (514) 340-8222, x24572 The Ottawa Hospital, Ottawa, ON; Study co-ordinator is at (613) 737-7700 (added <a href=\"https:\/\/www.wmfc.ca\/fr\/2022\/02\/23\/another-clinical-trial-available-in-canada-nemtabrutinib\/\"> [&#8230;]<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[28,20],"tags":[],"class_list":["post-4900","post","type-post","status-publish","format-standard","hentry","category-canadian-insights","category-news"],"_links":{"self":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/4900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/comments?post=4900"}],"version-history":[{"count":4,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/4900\/revisions"}],"predecessor-version":[{"id":5063,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/4900\/revisions\/5063"}],"wp:attachment":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/media?parent=4900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/categories?post=4900"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/tags?post=4900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}